Maternal and fetal outcomes of spinal tuberculosis in pregnancy: A systematic review and descriptive pooled analysis.

Neurosurg RevOct 2, 2026 (epub)
Clinical ResearchObstetrics & GynecologyInfectious DiseasesOpen access

Anil Regmi, Abdus Sami, Surakshya Baral et al.

✦ AI-curated · Sources linked

Condensed from the publisher's abstract. An xxcode editorial summary of this publication has not been generated yet.

From the abstract

Spinal tuberculosis (TB) in pregnancy is rare and poses diagnostic, neurological, and obstetric challenges. Data are limited to isolated case reports and small series, precluding evidence-based guidance on management and outcomes.

Reported results

Twenty-three case reports and small case series (no controls) encompassing 36 pregnancies were included. All patients received standard Anti Tubercular Therapy (ATT); 26 (72%) underwent surgery, mostly postpartum. Pooled live birth proportion was 0.77 (95% CI: 0.63-0.88). Full maternal neurological recovery was achieved in 0.85 (95% CI: 0.74-0.94).

Authors' conclusions

In published cases, timely ATT and selective surgical intervention were associated with high reported rates of live birth and maternal neurological recovery; however, these findings likely reflect selected best-case scenarios and require confirmation in prospective registries.

Source

PubMed · PMID 42825858Free full text on PubMed Central

Published in Neurosurg Rev. The text above is extracted from the publisher's own abstract and has not been edited by xxcode. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Obstetrics & Gynecology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.